2 min read

ID: 1113490

Short Link: https://gregory-ms.com/articles/1113490/

Discovery Date: 28 November 2022, 06:00:56 UTC

Published Date: 2022-11-27 11:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/36436320/?fc=20210216052009&ff=20221128010009&v=2.17.8

Manual Selection: none

Machine Learning Gaussian Naive Bayes Model: false

Abstract

Clin Biomech (Bristol, Avon). 2022 Nov 17;100:105826. doi: 10.1016/j.clinbiomech.2022.105826. Online ahead of print.

ABSTRACT

BACKGROUND: Fampridine has shown to improve walking speed, motor control, and balance in patients with multiple sclerosis. However, potential fampridine-induced changes in gait quality and underlying mechanisms, evaluated by three-dimensional gait analysis, are poorly examined. The aim was to examine if two weeks of fampridine treatment would improve gait quality (using Gait Profile Score and Gait Variable Scores from three-dimensional gait analysis) and gait function (using performance-based tests, spatiotemporal parameters, and self-perceived gait function).

METHODS: 14 participants with multiple sclerosis were included (9 women and 5 men, age 53.6 ± 12.8 years, disease duration 21 ± 9.1 years) in this cohort study. Tests were completed prior to fampridine and after 14 (± 1) days of treatment. Three-dimensional gait analyses were completed, and kinematic measures were calculated for overall gait quality using Gait Profile Score, and for joint-specific variables, Gait Variable Scores. Gait function was assessed using spatiotemporal parameters, performance-based tests, and a patient-reported outcome measure. Student's paired t-test/Wilcoxon signed rank test were used to compare baseline and follow-up variables. Sample size calculation for Gait Profile Score required at least 9 participants.

FINDINGS: No fampridine-induced improvements in gait quality were demonstrated. For gait function, improvements were found in performance-based tests (Timed 25-Foot Walk: -11.5%; Six Spot Step Test: -13.9%; 2-Minute Walk Test: 18.2%) and self-perceived gait function (12-itemMS Walking Scale: -35.2%).

INTERPRETATION: Although two weeks of fampridine treatment in patients with multiple sclerosis improved gait function, there was no change in overall kinematic quality of gait.

TRIAL REGISTRATION: This work was collected as a part of a registered clinical trial (MUST): ClinicalTrials.govNCT03847545.

PMID:36436320 | DOI:10.1016/j.clinbiomech.2022.105826

Noun Phrases in Title

  • Gait quality
  • function
  • fampridine treatment
  • patients
  • multiple sclerosis
  • A prospective cohort study
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.